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Recombinant inﬂuenza viruses that bear the single immunodominant CD8+ T cell epitope OVA257−264 or the CD4+ T cell epitope
OVA323−339 of the model antigen ovalbumin (OVA) have been useful tools in immunology. Here, we generated a recombinant
inﬂuenza virus, WSN-OVAI/II, that bears both OVA-speciﬁc CD8+ and CD4+ epitopes on its hemagglutinin molecule. Live and
heat-inactivatedWSN-OVAI/II viruseswereeﬃcientlypresentedbydendriticcellsinvitrotoOT-ITCRtransgenicCD8+Tcellsand
OT-II TCR transgenic CD4+ T cells. In vivo, WSN-OVAI/II virus was attenuated in virulence, highly immunogenic, and protected
mice from B16-OVA tumor challenge in a prophylactic model of vaccination. Thus, WSN-OVAI/II virus represents an additional
tool, along with OVA TCR transgenic mice, for further studies on T cell responses and may be of value in vaccine design.
1.Introduction
Recombinant inﬂuenza viruses represent a promising deliv-
ery system of foreign antigens that can be fused to viral
proteins, such as hemagglutinin (HA), neuraminidase (NA),
or nonstructural protein 1 (NS1), or can be expressed as
an individual whole protein ﬂanked with NA segment-
speciﬁc packaging signals [1–5]. Inﬂuenza viruses bearing
model antigens have been used as tools to address several
questions and long-standing issues in immune biology. In
particular, recombinant inﬂuenza viruses bearing the single
immunodominant CD8+ T cell epitope OVA257−264 or the
CD4+ T cell epitope OVA323−339 of chicken ovalbumin
(OVA) have been used in several studies to characterize T cell
responses [6–12].
HAengineeredtocarrysmallpolypeptidesfusedtoitsN-
terminus is eﬃciently expressed and stably incorporated into
retroviral particles without aﬀecting its fusion activity [13].
Recently, this strategy was adopted to generate recombinant
inﬂuenza viruses bearing relatively large domains of the
protective antigens of Bacillus anthracis toxin (domain 1 ,
the region responsible for binding to the lethal factor
and the edema factor (LEF) and domain 4, the receptor-
binding domain (RBD)) fused to the N-terminus of the
HA of A/Aichi/2/68 (H3N2) in the genetic background of
A/WSN/33 virus (H1N1) [14, 15]. The chimeric fusion
proteins, named HA/LEF and HA/RBD, were functionally
expressed during virus infection in mice and elicited anti-
body responses speciﬁc to both the viral HA and the protein
domains of the Bacillusanthracistoxin. Here, by using a sim-
ilar approach, we generated a recombinant inﬂuenza virus,
WSN-OVAI/II, bearing both OVA-speciﬁc CD8+ and CD4+
epitopes in its HA, and characterized the OVA-speciﬁc T cell
immune response in vitro and in vivo as well as its ability to
protect mice from challenge with the OVA-expressing tumor
cells B16-OVA in a prophylactic model of vaccination.2 Journal of Biomedicine and Biotechnology
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Figure1:Constructionofthemutanthemagglutinin(HA)segment.
Schematic representation of the HA/OVAI/II construct, containing
the OVA epitopes inserted after the HA signal peptide (SP). CT,
TM=cytoplasmic, transmembrane domains of HA, respectively.
2.MaterialsandMethods
2.1. Mice. Female C57BL/6J mice and the TCR-transgenic
mouse line OT-II, expressing a TCR that recognize the
OVA323−339 epitope,wereobtainedfromCharlesRiver,Calco,
Italy.TheTCR-transgenicmouselineOT-I,expressingaTCR
that recognize an H-2b-restricted OVA257−264 epitope, SIIN-
FEKL, was kindly supplied by Dr. M. Bellone (San Raﬀaele
Scientiﬁc Institute, Milan, Italy). For all experiments, mice,
aged 6–12 weeks, were maintained at the Istituto Superiore
di Sanit` a by following institutional guidelines and approved
protocols.
2.2. Generation of Recombinant WSN-OVAI/II Virus. The
coding sequences for the OVA257−264 (SIINFEKL) and
OVA323−339 (ISQAVHAAHAEINEAGR) T cell epitopes were
inserted into the HA gene of A/WSN/33 virus, between the
coding regions that correspond to the C-terminus of the HA
signal peptide (SP) and the N-terminus of the protein fol-
lowing signal peptidase cleavage. Speciﬁcally, a pair of com-
plementary oligonucleotides encoding the OVA epitopes,
designated OVAI/II, with ﬂanking ClaI/PstI sites (encoding
ESI and LQ amino acids, resp.) was inserted into the cloning
cassette generated at the 3  end of the signal peptide coding
sequenceofthepPolI-WSNHAplasmid[16],andcontaining
the GGGGD peptide arm, as described by Li et al. [14]
(Figure 1). The recombinant inﬂuenza WSN-OVAI/II virus
bearing both of the OVA-speciﬁc CD8+ and CD4+ epitopes
was generated by use of plasmid-driven reverse genetics,
as described by Neumann et al. [16]. The presence of the
inserted sequence was conﬁrmed by sequencing.
2.3. Antigen Presentation In Vitro. For the antigen pre-
sentation assays in vitro, CD8+ and CD4+ T cells were
isolated from spleens and lymph nodes of OT-I and OT-II
OVA TCR transgenic mice, respectively, by use of magnetic
sorting (Miltenyi Biotec), according to the manufacturer’s
protocol. CD11c-positive dendritic cells (DCs) were isolated
from the spleens of C57BL/6 mice by using MACS beads
(Miltenyi Biotec) and the purity of the enriched CD11c-
positive cell preparation ranged from 90% to 95%. DCs were
resuspended to 107 cells/mL in serum-free RPMI 1640, and
incubated with either live or heat-inactivated (HI) WSN-
OVAI/II virus (1000HAU/mL) for 1h at 37◦C, 5% CO2.
Heat inactivation was performed by incubating WSN-
OVAI/II virus at 56◦C for 30min in a water bath, and
virus fusion activity and inactivation were determined as
previously described [17]. After incubation, antigen-loaded
DCs were washed and cultured with 105 enriched OT-I or
OT-II cells for 48h, after which 0.5μCi/well [3H]thymidine
(Amersham Biosciences, UK) was added for 16h before
harvesting. For the carboxyﬂuorescein succinimidyl ester-
(CFSE-) based lymphoproliferation assay, live virus-pulsed
DCs were coincubated with 2 × 106 CFSE-labelled OT-
I or OT-II cells; 72h later, the cells were stained with
anti-CD8-phycoerythrin and anti-CD4-phycoerytrin (PE),
respectively, for ﬂow cytometry.
2.4. Experimental Infection. Five-week-old female C57BL/6J
mice, anesthetized with Avertin given intraperitoneally, were
inoculated intranasally (i.n.) with 50μLo fW S N - O V A I/II
v i r u sa td i ﬀerent dilutions (ﬁve mice per dilution) and
observed for 21 days to determine the minimal dose lethal
to 50% of mice (MLD50). For virological analysis, mice were
inoculated with 3 × 105 PFU of WSN-OVAI/II virus or 5 ×
102 PFU of WSN virus, and virus titres in the lungs and nasal
turbinates were determined 3 days and 6 days after infection
by use of MDCK cells, as described previously [18].
2.5. Immunization and Tumor Challenge. Female C57BL/6J
mice were i.n. immunized with 3 × 105 PFU of WSN-
OVAI/II virus or 5 × 102 PFU of WSN virus. Nine days
later, ﬁve mice from each group were sacriﬁced to obtain
spleens and mediastinal lymph nodes (MLN), and epitope-
speciﬁc T cell responses were determined by using a mouse
IFN-γ enzyme-linked immunospot assay (ELISPOT) kit
(Pharmingen,BD).Speciﬁcally,asingle-cellsuspensionfrom
lymphoid tissues was cultured with either OVA257−264 or the
viral nucleoprotein (NP366−374)p e p t i d e ,w h e r e a se n r i c h e d
CD4+ T cells from the MLN were cultured for 48h with
the OVA323−339 peptide and irradiated (2.500rads) na¨ ıve
splenocytes. Tumor challenge experiments were carried out
by injecting intravenously (i.v.) 3 × 105 B16-OVA cells into
groups of mice that had been immunized three weeks earlier
with WSN or WSN-OVAI/II virus. Twelve days after tumor
cell injection, eight mice from each group were sacriﬁced,
and lung metastases were enumerated under a dissection
microscope. Nonimmunized mice served as na¨ ıve controls.
In addition, the frequency of SIINFEKL-speciﬁc IFN-γ-
producing T cells was measured by using the ELISPOT assay
on spleen-derived lymphocytes.
3. Results
The recombinant inﬂuenza WSN-OVAI-II virus bearing both
the OVA-speciﬁc CD8+ and CD4+ epitopes was generated
by introducing the coding sequences into the HA gene of
A/WSN/33 virus, after the coding region of the HA signal
peptide (SP), and the GGGGD peptide arm, as described
by Li et al. [14]( Figure 1). The rescued virus replicated in
tissue culture with a titer ranging from 5×106 to 107 plaque-
forming units (PFU)/mL.
We ﬁrst determined whether the OVA-speciﬁc T cell
epitopes of WSN-OVAI−II v i r u sw e r ee ﬃciently presented
to antigen-speciﬁc T cells. To this end, the capacity ofJournal of Biomedicine and Biotechnology 3
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Figure 2: Presentation of WSN-OVAI/II virus by dendritic cells (DCs) in vitro to OVA-speciﬁc CD8+ and CD4+ T cells. (a) Splenic DCs
were incubated with either live or heat-inactivated (HI) WSN-OVAI/II virus and then washed and titrated in microtiter plates. OT-I cells and
OT-II cells were added to the cultures (105/well), and T cell proliferation was estimated by use of [3H]thymidine incorporation two days
later. The data shown are the means (±SEM) from triplicate cultures. (b) CFSE-labelled na¨ ıve OT-I and OT-II cells were coincubated with
live virus-pulsed or control DCs. Three days later, proliferation of CD8+ and CD4+ T cells was determined by using ﬂow cytometry. The
results shown are representative of three experiments.
splenic DCs to process and present both live and HI
WSN-OVAI-II viruses was assessed by using an in vitro
proliferation assay of na¨ ıve OVA-speciﬁc CD8+ T and CD4+
T cells derived from OT-I and OT-II TCR-transgenic mice,
respectively. Live virus-loaded DCs eﬃciently processed and
presented both OVA-speciﬁc epitopes on MHC class I and
II molecules, whereas there was no response with uninfected
DCs(Figure 2(a)). CFSE-labelled transgenic T cells were also
used to monitor antigen-speciﬁc proliferation due to the
progressive halving of the dye ﬂuorescence following cell
division. WSN-OVAI/II virus-loaded DCs were responsible
for vigorous proliferation of OT-I and OT-II cells within the
CD8+ and CD4+ gated populations, respectively, compared
to unloaded- or WSN virus-loaded DCs (Figure 2(b)).
Furthermore, our data indicate that the OVA-speciﬁc MHC
class I-restricted epitope located on the HA of whole HI
WSN-OVAI/II virus was eﬃciently cross-presented by DCs
to CD8+ T cells (Figure 2(a)). The binding and fusogenic
functions of HI WSN-OVAI/II virus were intact as assessed
by standard hemagglutinating and hemolytic assays, respec-
tively, thus conﬁrming the importance of a functional HA
to access the cytoplasm of DCs [17]. The higher T cell
proliferation of OT-I compared to OT-II cells induced by
DCs loaded with HI WSN-OVAI/II virus, bearing equimolar
amounts of both epitopes, correlates with previous data
showing that the cell-associated antigen is more eﬃciently
presented to CD8+ than to CD4+ T cells [19].
To determine the immunogenicity of the WSN-OVAI/II
virusinC57BL/6Jmice,weﬁrstdetermined itspathogenicity
relative to the wild-type WSN virus. None of the inoculated
mice died, even those inoculated with doses of WSN-
OVAI/II v i r u sa sh i g ha s1 0 6 PFU, whereas the wild-type4 Journal of Biomedicine and Biotechnology
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Figure 3:ReplicationofWSN-OVAI/II virusinmice.C57BL/6Jmice
were inoculated i.n. under anaesthesia with 5 × 102 PFU of WSN
virus or 3 × 105 PFU of WSN-OVAI/II virus, and sacriﬁced on days
3 and 6 after infection for virus titration in lungs on MDCK cells.
The values presented are averages of triplicate wells; the error bars
indicate the standard deviation.
WSN virus killed all of the mice at this dose (data not
shown). Pulmonary viral loads measured 3 and 6 days after
infection in mice inoculated with 3 × 105 PFU of WSN-
OVAI/II virus (average titres of 4.1 and 2.3log10 TCID50/lung,
resp.) were about four logs lower than those observed for
mice inoculated with 5 × 102 PFU of the wild-type WSN
virus (Figure 3). Moreover, we could not detect virus in the
nasal turbinates of the WSN-OVAI/II-infected mice, whereas
detectable viral titres were measured in the nasal turbinates
of the WSN-infected animals on day 3 and 6 after infection
(data not shown). Although the recombinant virus did not
replicate as eﬃciently as the WSN virus, we used the above
viral doses to immunize mice and measured comparably
high levels of NP-speciﬁc CD8+ T cells for both viruses
in the MLN and in the spleen at day 9 after infection
(Figure 4(a)). The OVA-speciﬁc CD8+ T cell response was
also vigorous, as determined by ex vivo IFN-γ release
by lymphoid cells after the addition of speciﬁc peptides
(Figure 4(a)) indicating that the attenuated recombinant
viruswaseﬃcientlyimmunogenicforCD8+Tcells.Toassess
whether the engineered OVA-speciﬁc CD4+ T cell epitope
was also presented in the context of infection, we measured
the OVA323−339-speciﬁc CD4+ T cells secreting IFN-γ in the
enriched CD4+ T cell population from the MLN of these
mice. WSN-OVAI/II-infected mice produced an average of
120 spot-forming cells (SFC)/million cells, whereas WSN-
infected mice gave no OVA-speciﬁc response (Figure 4(b)).
Although the insertion of foreign epitopes into the HA
of WSN-OVAI/II virus was responsible for the attenuated
phenotype, the double OVA recombinant virus was still
replicating and inducing a remarkable OVA-speciﬁc T cell
response in mice.
Recombinant viral vectors expressing the immunodom-
inant OVA-speciﬁc CD8+ T cell epitope induce protective
immunity against challenge with lethal doses of malignant
melanoma cells expressing OVA [20, 21]. Moreover, recom-
binant inﬂuenza viruses expressing a tumor-associated anti-
gen have been previously shown to elicit eﬃcient antitumor
responses and to induce tumor inhibition in experimental
murine cancer models [22, 23]. We, therefore, examined the
ability of WSN-OVAI/II virus to protect mice against tumors
by using the tumor cell line B16-OVA (OVA-transfected B16
cells), which cause pulmonary metastases when given intra-
venously. Immunization with WSN-OVAI/II virus protected
mice from lung metastases, as measured 12 days after tumor
challenge, compared to nonimmunized mice (Figure 5(a)).
The antitumor immunity was OVA-speciﬁc, as all of the
mice immunized with the parental WSN virus developed
tumors. We also found that WSN-OVAI/II virus-immunized
mice produced a stronger OVA257−264 (SIINFEKL-)speciﬁc
CD8+ T cell response than did either the nonimmunized
mice or the wild-type WSN virus-immunized mice, as
measured by ex vivo ELISPOT with pooled spleens on day 12
posttumor challenge (Figure 5(b)). The higher OVA257−264-
speciﬁc CD8+ T cell response detected in WSN-OVAI/II
virus-immunized mice that were subsequently challenged
with B16-OVA cells correlated with the presence of OVA-
speciﬁcmemoryTcellsinthesemicebeforetumorchallenge.
4. Discussion
Here, we engineered a recombinant inﬂuenza WSN-OVAI/II
virus to bear the OVA-speciﬁc CD4+ and CD8+ T cell
epitopes on its viral HA. This virus showed an attenuated
phenotype and was highly immunogenic in mice. The
eﬀective proliferation of OVA-speciﬁc CD8+ T cells in vitro
with HI WSN-OVAI/II virus-loaded DCs is in agreement
withpreviousdatashowingthatinactivatedinﬂuenzaviruses
that maintain their fusogenic properties are eﬃciently cross-
presented by DCs [17]. The presence of both OVA T
cell epitopes on the same viral HA protein provides an
additional tool, along with OVA-speciﬁc TCR transgenic
mice, to investigate antigen processing and presentation by
nonreplicating inﬂuenza virus-loaded DCs, in the context
of MHC class I and class II. The double OVA recombinant
v i r u st h u sr e p r e s e n t sa na t t r a c t i v ed e l i v e r ys y s t e mf o ru s ei n
studies that explore new vaccination strategies for inducing
virus-speciﬁc memory CD8+ T cells. Moreover, the ﬁnding
that foreign epitopes located on the HA of inactivated
recombinant inﬂuenza virions are eﬃciently cross-presented
to speciﬁc CD8+ T cells oﬀers interesting opportunities
to further explore the use of recombinant inﬂuenza virus-
based nonreplicating immunogens. In particular, this feature
could be used to develop virosomes, as antigen delivery
systems, since antigen encapsulation inside the virosomal
particles is usually required for cytosolic delivery upon
membrane fusion and for proteasome processing to induce
CTL responses [24].Journal of Biomedicine and Biotechnology 5
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Figure 4: T cell responses in WSN-OVAI/II virus-infected mice. C57BL/6J mice were immunized i.n. with 5 × 102 PFU of WSN virus or
3 × 105 PFU of WSN-OVAI/II virus, and sacriﬁced on day 9 for measuring epitope-speciﬁc CD8+ T cell responses in mediastinal lymph
nodes (MLN) and spleens (a) and CD4+ T cell responses in MLN (b), respectively, by use of an IFN-γ ELISPOT assay with the indicated
peptides. The values presented are averages of triplicate wells; the error bars indicate the standard deviation. The data are representative of
three experiments. ∗P<0.05 comparing WSN- versus WSN-OVAI/II-infected mice.
Our results also show that immunization with WSN-
OVAI/II v i r u sp r o t e c t sm i c ef r o mB 1 6 - O V At u m o rc h a l l e n g e .
Here, we did not directly address the question of whether
the double OVA recombinant virus has advantages over
the existing recombinant viruses that bear the single
OVA epitopes. Although the induction of OVA257−264
(SIINFEKL-)speciﬁc CD8+ T cells in the context of viral
infection may be suﬃcient to provide protective immunity,
it is plausible that the simultaneous induction of tumor-
speciﬁc CD4+ T cells may participate in interactions that
shape the protective response against tumors [21]. This is
particularly true if tumor-speciﬁc immune responses are
induced with nonreplicating immunogens and thus in the
presence of a poor inﬂammatory response. Recent studies
suggest that abnormalities of the immune response in
tumor-bearing hosts correlate with the induction of immune
tolerance toward tumor-associated antigens and with the
functional suppression of antitumor T cell eﬀectors due to
myeloid-derived suppressor cells [25, 26]. Thus, combining
WSN-OVAI/II virus infection and adoptive transfer of OVA-
speciﬁc TCR transgenic T cells in mice bearing OVA-
expressing tumors may help dissect the immunoregulatory
mechanisms responsible for tumor-induced tolerance and
immune suppression and may provide useful information
for rational design of cancer immunotherapy.
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